Dilaudid patient education Dilaudid; Dilaudid-HP. Descriptions. Hydromorphone injection is used to Español العربية 简体中文. © Mayo Foundation for Medical Education Dilaudid patient education IV slowly over 2-3 min but respiration needs to be monitored. What Drugs, Substances, or Supplements Interact with Dilaudid?Dilaudid may interact with alcohol, other narcotic pain medications, sedatives, tranquilizers, muscle relaxers, other medicines that can make you sleepy or slow your breathing, buprenorphine, butorphanol, nalbuphine, pentazocine, atropine, belladonna, benztropine, dimenhydrinate, methscopolamine, scopolamine, bladder or urinary medicines, bronchodilators, irritable bowel medicines, or ulcer medications. Tell your doctor all medications and supplements you use. Dilaudid During Pregnancy and BreastfeedingDilaudid should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus or breastfeeding infant; the drug should not be used for labor or delivery; pregnant women taking the medication will usually cause the fetus/infant to be dependent on opioids and likely will have other effects on the infant. There are no Dilaudid studies on pediatric patients. Additional InformationOur Dilaudid and Dilaudid Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. WARNINGRISK OF MEDICATION ERRORS; ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFETHREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTSRisk of Medication ErrorsEnsure accuracy when prescribing, dispensing, and administering DILAUDID Oral Solution. Dosing errors due to confusion between mg and mL can result in accidental overdose and death [see DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS].Addiction, Abuse, and MisuseDILAUDID Oral Solution and DILAUDID Tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing DILAUDID Oral Solution or DILAUDID Tablets, and monitor all patients regularly for the development of these behaviors and conditions [see WARNINGS AND PRECAUTIONS].Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the WARNINGS AND PRECAUTIONS]. Under the requirements of the REMS, drug companies with approved opioid analgesic complete a REMS-compliant education program, counsel patients and/or their caregivers, with every prescription, on safe use, serious Dilaudid patient education pregnancy. Be sure to educate the patient on these so they PCA dilaudid will most likely be needed if the patient does not receive neuraxial duramorph. Dilaudid patient education Patient education: Head injury in adults (The Basics) Patient education: Labyrinthitis (The Basics) Patient education: Meniere disease (The Basics) Patient education: Vestibular schwannoma (acoustic neuroma) (The Basics) Beyond the Basics Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These Dilaudid patient education Patient education: Nutrition before and during pregnancy (The Basics) Patient education: Restless legs syndrome (The Basics) Patient education: Angiodysplasia of the GI tract (The Basics) Patient education: Medicines for chronic kidney disease (The Basics) Patient education: Good food sources of iron (The Basics) Dilaudid patient education hydromorphone (Dilaudid) Do not do activities that may lead to injury. Source: Allina Health's Patient Education Department, Hip Replacement, eighth edition Dilaudid patient education Patient education: Epididymitis and orchitis (The Basics) Patient education: Urethritis (The Basics) Patient education: Bartholin gland cyst (The Basics) Patient education: Mycoplasma genitalium (The Basics) Beyond the Basics Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are Dilaudid patient education To underestimate a patient's 24-hour DILAUDID dosage than to overestimate the 24-hour dosage and manage an adverse reaction due to overdose.In general, it is safest to start DILAUDID therapy by administering half of the usual starting dose every 3 to 6 hours for DILAUDID Oral Solution; and every 4 to 6 hours for DILAUDID Tablets. The dose of DILAUDID can be gradually adjusted until adequate pain relief and acceptable side effects have been achieved.Conversion from DILAUDID Oral Solution or DILAUDID Tablets to Extended-Release Hydromorphone HydrochlorideThe relative bioavailability of DILAUDID Oral Solution and DILAUDID Tablets compared to extended-release hydromorphone is unknown, so conversion to extended-release hydromorphone may lead to increased risk of excessive sedation and respiratory depression. Dosage Modifications in Patients with Hepatic ImpairmentInitiate treatment with one-fourth to one-half the usual DILAUDID starting dose depending on the degree of impairment. Dosage Modifications in Patients with Renal ImpairmentInitiate treatment with one-fourth to one-half the usual DILAUDID starting dose depending on the degree of impairment. Titration and Maintenance of TherapyIndividually titrate DILAUDID Oral Solution or DILAUDID Tablets to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving DILAUDID Oral Solution or DILAUDID Tablets to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and other adverse reactions, as well as to reassess for the development of addiction, abuse, or misuse. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the DILAUDID Oral Solution or DILAUDID Tablets dosage. If after increasing the dosage, unacceptable opioid-related adverse reactions are observed (including an increase in pain after a dosage increase), consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.A supplemental dose of 5 to 15% of the total daily usage may be administered every two hours on an as-needed basis. Safe Reduction or Discontinuation of DILAUDID Oral Solution or DILAUDID TabletsDo not abruptly discontinue DILAUDID Oral Solution and DILAUDID Tablets in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to Patient was educated on Dilaudid and its mechanism of action as follows: Dilaudid is an opioid pain medication that contains Hydromorphone. Hydromorphone is derived from Morphine, which is an opioid alkaloid like Thebaine and Codeine. Dilaudid is used to relieve moderate to severe pain. Dilaudid binds with the opioid receptors in the brain and block the release of excitatory neurotransmitters Dilaudid patient education Patient education: Nutrition before and during pregnancy (The Basics) Patient education: Restless legs syndrome (The Basics) Patient education: Angiodysplasia of the GI tract (The Basics) Patient education: Medicines for chronic kidney disease (The Basics) Patient education: Good food sources of iron (The Basics) Dilaudid patient education Patient Education and Teaching. When providing patients with education about Dilaudid, it s important to follow these guidelines: Advise patient to take only as prescribed and not to change the dose without consulting a healthcare professional. Advise patient that hydromorphone is a drug with known abuse potential. Dilaudid patient education (Dilaudid). 2-4 mg by mouth every. 4-6 hours PRN pain. Titrate Intermountain approved patient education can be downloaded from the Dilaudid patient education These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Patient education: Genital herpes (The Basics) Patient education: Anogenital warts (The Basics) Patient education: Syphilis (The Basics) Patient education: Sexually transmitted infections (The Basics) Patient education: Urethritis (The Dilaudid patient education Patient education: H. pylori infection (The Basics) Patient education: Peptic ulcers (The Basics) Patient education: Stomach polyps (The Basics) Patient education: Stomach cancer (The Basics) Beyond the Basics Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients Dilaudid patient education 3 to 6 hours as needed for pain, and at the lowest dose necessary to achieve adequate analgesia. Titrate the dose based upon the individual patient's response to their initial dose of DILAUDID Oral Solution.Initiate treatment with DILAUDID Tablets in a dosing range of 2 mg to 4 mg, orally, every 4 to 6 hours as needed for pain, and at the lowest dose necessary to achieve adequate analgesia. Titrate the dose based upon the individual patient's response to their initial dose of DILAUDID Tablets. Patient Access to Naloxone for the Emergency Treatment of Opioid OverdoseDiscuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with DILAUDID Oral Solution or DILAUDID Tablets.Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program).Consider prescribing naloxone, based on the patient's risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. The presence of risk factors for overdose should not prevent the proper management of pain in any given patient.Consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose. Initial DosageInitiating Treatment with DILAUDID Oral Solution or DILAUDID TabletsDilaudid Oral SolutionInitiate treatment with DILAUDID Oral Solution in a dosing range of 2.5 mL to 10 mL, 2.5 mg to 10 mg, every 3 to 6 hours as needed for pain, and at the lowest dose necessary to achieve adequate analgesia. Titrate the dose based upon the individual patient's response to their initial dose of DILAUDID Oral Solution.Dilaudid TabletsInitiate treatment with DILAUDID Tablets in a dosing range of 2 mg to 4 mg, orally, every 4 to 6 hours as needed for pain, and at the lowest dose necessary to achieve adequate analgesia. Titrate the dose based upon the individual patient's response to their initial dose of DILAUDID Tablets.Conversion from Other Opioids to DILAUDID Oral Solution or DILAUDID TabletsThere is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dosage of DILAUDID Oral Solution or DILAUDID Tablets. It is safer Dilaudid patient education hydromorphone (Dilaudid) Do not do activities that may lead to injury. Source: Allina Health's Patient Education Department, Hip Replacement, eighth edition Dilaudid patient education Patient education: Bacterial vaginosis (The Basics) Patient education: Vaginal discharge (The Basics) Patient education: Mycoplasma genitalium (The Basics) Patient education: Probiotics (The Basics) Beyond the Basics Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for Dilaudid patient education Dilaudid. JUNO. Medsurge. Injection. 2 mg/1 mL. On the advice Assist with appropriate patient/carer education regarding HYDROmorphone Dilaudid patient education Patient education: Addison disease (The Basics) Patient education: Cushing syndrome (The Basics) Patient education: Adrenal crisis (The Basics) Patient education: Panhypopituitarism (The Basics) Beyond the Basics Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for Dilaudid patient education Patient was educated on Dilaudid and its mechanism of action as follows: Dilaudid is an opioid pain medication that contains Hydromorphone. Hydromorphone is derived from Morphine, which is an opioid alkaloid like Thebaine and Codeine. Dilaudid is used to relieve moderate to severe pain. Dilaudid binds with the opioid receptors in the brain and block the release of excitatory neurotransmitters Dilaudid patient education Due to overdose.If the decision is made to convert to Hydromorphone Hydrochloride Injection from another opioid analgesic using publicly available data, convert the current total daily amount(s) of opioid(s) received to an equivalent total daily dose of DILAUDID INJECTION and reduce by one-half due to the possibility of incomplete cross tolerance. Divide the new total amount by the number of doses permitted based on dosing interval (e.g., 8 doses for every-three-hour dosing). Titrate the dose according to the patient's response.Dosage Modifications In Patients With Hepatic ImpairmentStart patients with hepatic impairment on one-fourth to one-half the usual DILAUDID INJECTION starting dose depending on the extent of impairment [see CLINICAL PHARMACOLOGY].Dosage Modifications In Patients With Renal ImpairmentStart patients with renal impairment on one-fourth to one-half the usual DILAUDID INJECTION starting dose depending on the degree of impairment [see CLINICAL PHARMACOLOGY].Titration And Maintenance Of TherapyTitrate the dose based upon the individual patient’s response to their initial dose of DILAUDID INJECTION. Individually titrate DILAUDID INJECTION to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving DILAUDID INJECTION to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and other adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse [see WARNINGS AND PRECAUTIONS]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the DILAUDID INJECTION dosage. If after increasing the dosage, unacceptable opioid-related adverse reactions are observed (including an increase in pain after a dosage increase), consider reducing the dosage [see WARNINGS AND PRECAUTIONS]. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.Safe Reduction Or Discontinuation Of DILAUDID INJECTIONWhen a patient who has been taking DILAUDID INJECTION regularly and may be physically dependent no longer requires therapy with DILAUDID INJECTION, taper the dose gradually, by 25% to 50% every 2 to 4 days, while monitoring carefully for signs and pregnancy. Be sure to educate the patient on these so they PCA dilaudid will most likely be needed if the patient does not receive neuraxial duramorph. Dilaudid patient education Patient education: H. pylori infection (The Basics) Patient education: Peptic ulcers (The Basics) Patient education: Stomach polyps (The Basics) Patient education: Stomach cancer (The Basics) Beyond the Basics Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients Dilaudid patient education Patient education: Deciding to have a hip replacement (The Basics) Patient education: Disease-modifying antirheumatic drugs (DMARDs) (The Basics) Patient education: Physical activity for people with arthritis (The Basics) Patient education: Rheumatoid arthritis (The Basics) Patient education: Rheumatoid arthritis and pregnancy (The Basics) Dilaudid patient education Patient education: Angioedema (The Basics) Patient education: Primary biliary cholangitis (The Basics) Patient education: Chronic hives (The Basics) Patient education: Inducible hives (The Basics) Patient education: Itchy skin (The Basics) Beyond the Basics Beyond the Basics patient education pieces are longer, more sophisticated, and more Dilaudid patient education by PS WHITECAR 2024 Cited by 49Hydromorphone (Dilaudid) In addition, physicians may not anticipate predictable side effects of narcotics and may not educate their patients Dilaudid patient education Patient education: Addison disease (The Basics) Patient education: Cushing syndrome (The Basics) Patient education: Adrenal crisis (The Basics) Patient education: Panhypopituitarism (The Basics) Beyond the Basics Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for Dilaudid patient education Due to overdose.If the decision is made to convert to Hydromorphone Hydrochloride Injection from another opioid analgesic using publicly available data, convert the current total daily amount(s) of opioid(s) received to an equivalent total daily dose of DILAUDID INJECTION and reduce by one-half due to the possibility of incomplete cross tolerance. Divide the new total amount by the number of doses permitted based on dosing interval (e.g., 8 doses for every-three-hour dosing). Titrate the dose according to the patient's response.Dosage Modifications In Patients With Hepatic ImpairmentStart patients with hepatic impairment on one-fourth to one-half the usual DILAUDID INJECTION starting dose depending on the extent of impairment [see CLINICAL PHARMACOLOGY].Dosage Modifications In Patients With Renal ImpairmentStart patients with renal impairment on one-fourth to one-half the usual DILAUDID INJECTION starting dose depending on the degree of impairment [see CLINICAL PHARMACOLOGY].Titration And Maintenance Of TherapyTitrate the dose based upon the individual patient’s response to their initial dose of DILAUDID INJECTION. Individually titrate DILAUDID INJECTION to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving DILAUDID INJECTION to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and other adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse [see WARNINGS AND PRECAUTIONS]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the DILAUDID INJECTION dosage. If after increasing the dosage, unacceptable opioid-related adverse reactions are observed (including an increase in pain after a dosage increase), consider reducing the dosage [see WARNINGS AND PRECAUTIONS]. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.Safe Reduction Or Discontinuation Of DILAUDID INJECTIONWhen a patient who has been taking DILAUDID INJECTION regularly and may be physically dependent no longer requires therapy with DILAUDID INJECTION, taper the dose gradually, by 25% to 50% every 2 to 4 days, while monitoring carefully for signs and Dilaudid patient education Patient education: Bacterial vaginosis (The Basics) Patient education: Vaginal discharge (The Basics) Patient education: Mycoplasma genitalium (The Basics) Patient education: Probiotics (The Basics) Beyond the Basics Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for Dilaudid patient education Hydromorphone, Hydrocodone, Dilaudid, Adderall, Ritalin, and OxyContin coordination of care, patient education, monitoring, and surveillance Dilaudid patient education Patient education: H. pylori infection (The Basics) Patient education: Peptic ulcers (The Basics) Patient education: Stomach polyps (The Basics) Patient education: Stomach cancer (The Basics) Beyond the Basics Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients Dilaudid patient education Important : This booklet is created for patient education only and does not replace Dilaudid, Morphine. Statex, Oxycodone. Supeudol, Tramadol. Codeine Dilaudid patient education Dilaudid. JUNO. Medsurge. Injection. 2 mg/1 mL. On the advice Assist with appropriate patient/carer education regarding HYDROmorphone Dilaudid patient education Of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.Severe HypotensionDILAUDID INJECTION may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) [see DRUG INTERACTIONS]. Monitor these patients for signs of hypotension after initiating or titrating the dosage of DILAUDID INJECTION. In patients with circulatory shock, DILAUDID INJECTION may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of DILAUDID INJECTION in patients with circulatory shock.Risks Of Use In Patients With Increased Intracranial Pressure, Brain Tumors, Head Injury, Or Impaired ConsciousnessIn patients who may be susceptible to the intracranial effects of CO2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), DILAUDID INJECTION may reduce respiratory drive, and the resultant CO2 retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with DILAUDID INJECTION.Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of DILAUDID INJECTION in patients with impaired consciousness or coma.Risks Of Use In Patients With Gastrointestinal ConditionsDILAUDID INJECTION is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.The hydromorphone in DILAUDID INJECTION may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.Increased Risk Of Seizures In Patients With Seizure DisordersThe hydromorphone in DILAUDID INJECTION may increase the frequency of seizures in patients with seizure disorders and may increase the risk of seizures occurring in other clinical settings associated with seizures. Monitor patients with a history Patient education: H. pylori infection (The Basics) Patient education: Peptic ulcers (The Basics) Patient education: Stomach polyps (The Basics) Patient education: Stomach cancer (The Basics) Beyond the Basics Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients Dilaudid patient education Patient education: H. pylori infection (The Basics) Patient education: Peptic ulcers (The Basics) Patient education: Stomach polyps (The Basics) Patient education: Stomach cancer (The Basics) Beyond the Basics Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients Dilaudid patient education Patient Community Education. Hydromorphone. Pediatric Medication. Share. This Brand Names: Canada. APO-HYDROmorphone; APO-HYDROmorphone CR [DSC]; Dilaudid Dilaudid patient education Patient education: H. pylori infection (The Basics) Patient education: Peptic ulcers (The Basics) Patient education: Stomach polyps (The Basics) Patient education: Stomach cancer (The Basics) Beyond the Basics Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients Dilaudid patient education Provide education on pain management as part of the patient's treatment considering the patient's Dilaudid is a much stronger analgesic than Morphine. Dilaudid patient education pregnancy. Be sure to educate the patient on these so they PCA dilaudid will most likely be needed if the patient does not receive neuraxial duramorph. Dilaudid patient education Of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.Severe HypotensionDILAUDID INJECTION may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) [see DRUG INTERACTIONS]. Monitor these patients for signs of hypotension after initiating or titrating the dosage of DILAUDID INJECTION. In patients with circulatory shock, DILAUDID INJECTION may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of DILAUDID INJECTION in patients with circulatory shock.Risks Of Use In Patients With Increased Intracranial Pressure, Brain Tumors, Head Injury, Or Impaired ConsciousnessIn patients who may be susceptible to the intracranial effects of CO2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), DILAUDID INJECTION may reduce respiratory drive, and the resultant CO2 retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with DILAUDID INJECTION.Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of DILAUDID INJECTION in patients with impaired consciousness or coma.Risks Of Use In Patients With Gastrointestinal ConditionsDILAUDID INJECTION is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.The hydromorphone in DILAUDID INJECTION may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.Increased Risk Of Seizures In Patients With Seizure DisordersThe hydromorphone in DILAUDID INJECTION may increase the frequency of seizures in patients with seizure disorders and may increase the risk of seizures occurring in other clinical settings associated with seizures. Monitor patients with a history Dilaudid patient education Brand Names: Canada. APO-HYDROmorphone; APO-HYDROmorphone CR [DSC]; Dilaudid Spanish [Español]. Contact Us. Request a new patient education resource Dilaudid patient education by PS WHITECAR 2024 Cited by 49Hydromorphone (Dilaudid) In addition, physicians may not anticipate predictable side effects of narcotics and may not educate their patients Dilaudid patient education Patient education: Deciding to have a hip replacement (The Basics) Patient education: Disease-modifying antirheumatic drugs (DMARDs) (The Basics) Patient education: Physical activity for people with arthritis (The Basics) Patient education: Rheumatoid arthritis (The Basics) Patient education: Rheumatoid arthritis and pregnancy (The Basics) Dilaudid patient education Patient education: Chronic kidney disease (Beyond the Basics) Patient education: Health and nutrition during breastfeeding (Beyond the Basics) Patient education: Hives (urticaria) (Beyond the Basics) Patient education: Peptic ulcer disease (Beyond the Basics) Patient education: Warfarin (Beyond the Basics) Dilaudid patient education Patient Education Next; Topics Next. acog.org ACOG Clinical Green Journal O G Patient Education. Patient Education Materials For Patients. Topics. Dilaudid patient education Generic name: hydromorphone hydrochloride 2mgDosage form: oral liquid, tabletsDrug class: Opioids (narcotic analgesics)Medically reviewed by Drugs.com. Last updated on Jan 8, 2024. Important Dosage and Administration InstructionsEnsure accuracy when prescribing, dispensing, and administering DILAUDID Oral Solution to avoid dosing errors due to confusion between mg and mL, which could result in accidental overdose and death. Ensure the proper dose is communicated and dispensed. When writing prescriptions, include both the total dose in mg and the total dose in volume.Instruct patients and caregivers on how to accurately measure and take or administer the correct dose of DILAUDID Oral Solution.Strongly advise patients and caregivers to always use a graduated oral syringe or measuring cup, with metric units of measurements (i.e., mL), to correctly measure the prescribed amount of medication.Inform patients and caregivers that oral dosing devices may be obtained from their pharmacy and to never use household teaspoons or tablespoons to measure DILAUDID Oral Solution.DILAUDID Oral Solution and DILAUDID Tablets should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks.Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals. Because the risk of overdose increases as opioid doses increase, reserve titration to higher doses of DILAUDID Oral Solution and DILAUDID Tablets for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks.Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an opioid analgesic. Clinical guidelines on opioid prescribing for some acute pain conditions are available.There is variability in the opioid analgesic dose and duration needed to adequately manage pain due both to the cause of pain and to individual patient factors. Initiate the dosing regimen for each patient individually, taking into account the patient's underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse.Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with DILAUDID Oral Solutions and DILAUDID Tablets. Consider this risk when selecting an initial dose and when making dose adjustments.Initiate treatment with DILAUDID Oral Solution in a dosing range of 2.5 mL to 10 mL, 2.5 mg to 10 mg, every Patient education: Deciding to have a hip replacement (The Basics) Patient education: Disease-modifying antirheumatic drugs (DMARDs) (The Basics) Patient education: Physical activity for people with arthritis (The Basics) Patient education: Rheumatoid arthritis (The Basics) Patient education: Rheumatoid arthritis and pregnancy (The Basics) Dilaudid patient education Patient education: H. pylori infection (The Basics) Patient education: Peptic ulcers (The Basics) Patient education: Stomach polyps (The Basics) Patient education: Stomach cancer (The Basics) Beyond the Basics Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients Dilaudid patient education Patient education: Chronic kidney disease (Beyond the Basics) Patient education: Health and nutrition during breastfeeding (Beyond the Basics) Patient education: Hives (urticaria) (Beyond the Basics) Patient education: Peptic ulcer disease (Beyond the Basics) Patient education: Warfarin (Beyond the Basics) Dilaudid patient education Patient education: Headaches in adults (The Basics) Patient education: Migraine in adults (The Basics) Patient education: Headaches in children (The Basics) Patient education: Concussion in adults (The Basics) Beyond the Basics Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are Dilaudid patient education Patient Education and Teaching. When providing patients with education about Dilaudid, it s important to follow these guidelines: Advise patient to take only as prescribed and not to change the dose without consulting a healthcare professional. Advise patient that hydromorphone is a drug with known abuse potential. Dilaudid patient education
Patient Education and Support for
Patient Education - askhowe.perkins.org